DSIP
DSIP (delta sleep-inducing peptide) is a nonapeptide studied in sleep-architecture research models.
We have not published an audit on DSIP. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
How it is thought to work
Sleep-related neuropeptide signaling.
DSIP is a small nine-amino-acid peptide that appears to modulate sleep architecture, particularly deep, slow-wave sleep, rather than acting as a direct sedative, though exactly how it does this at the receptor level is still not fully understood.
Reported side effects
In early human studies DSIP was generally well tolerated, with some subjects experiencing mild, transient headache, nausea, or dizziness, though long-term safety has not been formally established and theoretical risks such as immunogenicity and HPA-axis interactions have been flagged by the FDA.
Who should avoid it
People who are pregnant or breastfeeding, children, those with untreated sleep apnea, active substance dependence, adrenal or thyroid disease, or anyone taking sedating medications should avoid DSIP due to lack of safety data or potential interactions.
What gets monitored
CBC with differential and comprehensive metabolic panel (CMP) at baseline; optional TSH and free T4, and A1c as needed. [Source: Peptide Dosing Protocols]
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for DSIP or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| 100-300 mcg subcutaneous; 25 nmol/kg IV (~1.5 mg for 70 kg person) | Once daily before bed; or every 2-3 dayshave not been established. | subcutaneous or intranasal | Peptide Protocol WikiWhat it saysHide(secondary reference; provider confirmation required). |
| Standard: 100-200 mcg · Low: 100 mcg · High: 300 mcg | once daily5-7 nights · short course | SubQ | Peptide Dosing ProtocolsWhat it saysHide(secondary reference; provider confirmation required). The standard dosing for DSIP is 100-200 mcg subcutaneously once daily. |
- Once daily before bed; or every 2-3 dayshave not been established.
- subcutaneous or intranasal
- Peptide Protocol Wiki
What it saysHide
(secondary reference; provider confirmation required).
- once daily5-7 nights · short course
- SubQ
- Peptide Dosing Protocols
What it saysHide
(secondary reference; provider confirmation required). The standard dosing for DSIP is 100-200 mcg subcutaneously once daily.
- Bacteriostatic water
- 2.0 mL bacteriostatic water
Common questions
What is DSIP peptide?
DSIP, or delta sleep-inducing peptide, is a nine-amino-acid neuropeptide first isolated in 1974 from the cerebral venous blood of sleeping rabbits.
Is DSIP FDA-approved?
No. DSIP is not FDA-approved for any human indication.
What is a typical DSIP dose used in research?
Older human trials used 25 nmol/kg intravenously; community research planning today is mostly subcutaneous in the 100-300 mcg range.
How is DSIP reconstituted?
Add 2.0 mL of bacteriostatic water to a 10 mg vial for a 5 mg/mL working concentration.
Check 10 mg in 2 mL in the calculator →When is DSIP usually injected?
Most research write-ups describe a single evening subcutaneous dose 1-3 hours before intended sleep.
What are the reported side effects of DSIP?
Mild transient headache, nausea, and occasional dizziness have been reported.
How does DSIP compare to melatonin?
DSIP modulates sleep architecture, while melatonin mainly shifts sleep timing.
Is DSIP medical advice?
No, this page is an educational research reference.
Sources
- 01Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): a review. Neuroscience and Biobehavioral Reviews (1984)
- 02Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): an update. Peptides (1986)
- 03Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. Journal of Neurochemistry (2006)
- 04Schneider-Helmert D, Schoenenberger GA. The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep. Experientia (1981)
- 05Schneider-Helmert D. Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia. European Neurology (1987)
- 06Salgado-Puga K, et al. Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs. European Neurology (1987)
The reference sections above are imported from our compound knowledge base, which classes the evidence for DSIP as emerging. That classification is the knowledge base’s, not ours, our own grade appears only where an audit is linked above. Research use only; nothing here is medical advice or a protocol.
GHRH analog discussed for GH axis support.
Blend of CJC-1295 (GHRH analog) and Ipamorelin (GHRP), studied for growth-hormone-axis support, recovery, and body composition.
Epithalon (epitalon) is a synthetic tetrapeptide studied in telomere and pineal-axis research models.
Ipamorelin is a selective growth-hormone secretagogue studied in pituitary research models.
Selank is a synthetic heptapeptide analog of the immunomodulatory peptide tuftsin, studied in anxiolytic and neurotrophic research models.
Sermorelin is a synthetic 29-amino-acid analog of growth-hormone-releasing hormone (GHRH) studied in growth-hormone axis research.